Senores Pharmaceuticals Limited Stock Price Today (NSE: SENORES)

Senores Pharmaceuticals Limited

1376.9039.20 (2.77%)
Market Closed

Fundamental Score

...

Senores Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Senores Pharmaceuticals Limited share price today is 1376.90, down 2.77% on NSE/BSE as of 16 September 2026. Senores Pharmaceuticals Limited (SENORES) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of 6.34K (Cr). The 52-week high for SENORES share price is 1599.00 and the 52-week low is 662.45. At a P/E ratio of 48.48x, SENORES is currently trading above its industry average P/E of 34.89x. 0

Senores Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
1599.00
Low
1325.10
Volume
2.5L
Change
+6.16%

Senores Pharmaceuticals Limited share price chart: 6.16% return over the past month. 52-week high ₹1599.00, 52-week low ₹662.45.

Senores Pharmaceuticals Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
1424.201425.001355.601376.902.23L (Cr)
1470.001475.601400.001416.101.62L (Cr)
1452.001480.001437.101467.301.35L (Cr)
1489.801495.001460.001463.1091.24K (Cr)
1519.901525.001460.201488.602.33L (Cr)
1504.001532.001486.001509.803.74L (Cr)
1428.401512.001410.401497.504.04L (Cr)
1442.801465.901420.001428.401.24L (Cr)
1450.001462.401424.001430.401.12L (Cr)
1454.701478.801440.201449.501.70L (Cr)

Senores Pharmaceuticals Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
1442.301532.001355.601376.90-4.53%
1326.601599.001306.101432.80+8.01%
1343.401509.801287.901305.70-2.81%
1042.301360.001001.001329.90+27.59%
904.001194.40877.551120.65+23.97%
797.00947.70741.90899.20+12.82%
747.00801.40706.00759.60+1.69%
786.00849.40760.00764.90-2.68%
825.00876.50752.40787.95-4.49%
825.00849.10738.10822.20-0.34%
771.20832.00755.00823.70+6.81%
689.95790.00684.60771.20+11.78%

Returns & Performance

Poor

Return on Equity (ROE)

0.00%

Profit generated per ₹1 of shareholder equity

Good

Return on Capital (ROCE)

17.00%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

26.41%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Senores Pharmaceuticals Limited Valuation Check

Poor

Price to Earnings (P/E)

48.48x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Mid-cap
Balance of growth potential and stability.

Shareholding Pattern

Excellent

Promoter Holding

45.80%

% shares held by company founders/management

Poor

FII Holding

3.64%

% shares held by foreign institutional investors

Average

DII Holding

9.62%

% held by domestic mutual funds, LIC, banks

Poor

Promoter Pledged %

1.90%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

55.68%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

30.60%

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Good

Debt to Equity Ratio

0.35x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

7.36x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-528.53 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Senores Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of SENORES across key market metrics for learning purposes.

Positive Indicators

6 factors identified

Excellent ROCE Performance (17.00%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (26.41%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Robust Profit Growth (55.68%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (30.60%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Strong Interest Coverage (7.36x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Healthy Liquidity Position (Current Ratio: 3.00)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Risk Factors

5 factors identified

Below-Average Return on Equity (0.00%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Premium Valuation Risk (P/E: 48.48x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

High Price-to-Book Ratio (8.07x)

Observation: Trading at significant premium to book value.

Analysis: High P/B ratios may indicate overvaluation relative to asset base.

Negative Free Cash Flow (₹-528.53 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Senores Pharmaceuticals Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Senores Pharmaceuticals Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
44.7/100
1377
₹6340.62
48.5
Average
0.00%
Poor
17.00%
Good
0.4
Excellent
0.00%
66.4/100
1877
₹450228.65
37.2
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9426
₹249775.75
85.5
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4927
₹166759.24
78.7
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1139
₹113642.26
25.4
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1370
₹110675.45
32.8
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1926
₹104025.14
95.0
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1675
₹96391.01
26.2
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
2100
₹96017.92
17.4
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
41/100
1141
₹95306.90
29.5
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
61.5/100
2289
₹94539.83
46.3
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Senores Pharmaceuticals Limited PE Ratio History

Historical price-to-earnings ratio for SENORES — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202516.12₹822.2051x
FY 20246.83₹568.6083.3x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Senores Pharmaceuticals Limited Quarterly Performance

Latest quarterly metrics for SENORES — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

30.60%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

55.68%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Senores Pharmaceuticals Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for SENORES — calculated from daily price history

43RSI 14
Neutral — RSI 43

Momentum is balanced — neither overbought nor oversold.

SMA 50
1415
▼ Price below SMA 50 — Short-term bearish
SMA 200
1008
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
270K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Senores Pharmaceuticals Limited Financial Statements

Annual income statement, balance sheet and cash flow for Senores Pharmaceuticals Limited (SENORES) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Senores Pharmaceuticals Limited

Loading latest quarterly results...

About SENORES (Senores Pharmaceuticals Limited)

Senores Pharmaceuticals Ltd is a global pharmaceutical company dedicated to advancing healthcare through the discovery, development, and commercialization of innovative therapies. ...With a strong emphasis on research and development, Senores Pharmaceuticals is committed to addressing unmet medical needs across a broad range of therapeutic areas. The company's mission is to improve patient outcomes and enhance the quality of life for individuals worldwide by providing access to safe, effective, and affordable medicines. Senores Pharmaceuticals operates with the highest ethical standards and a focus on sustainability, ensuring that its business practices are environmentally responsible and socially conscious. They strive to be a trusted partner for healthcare professionals and patients, offering comprehensive support and resources to optimize treatment outcomes. Driven by a passion for scientific excellence, Senores Pharmaceuticals invests heavily in cutting-edge technologies and strategic collaborations to accelerate the development of novel therapeutics. The company's robust pipeline includes a diverse portfolio of products in various stages of development, targeting diseases with significant unmet needs. Senores Pharmaceuticals is committed to bringing innovative solutions to market that transform the lives of patients. Their experienced team of scientists, clinicians, and business professionals work collaboratively to navigate the complex regulatory landscape and ensure the timely delivery of high-quality products to patients in need. Senores Pharmaceuticals is dedicated to fostering a culture of innovation, collaboration, and patient-centricity, where every employee is empowered to make a difference in the world. Senores Pharmaceuticals is focused on expanding its global reach and strengthening its presence in key markets. The company's commercial operations are supported by a dedicated sales and marketing team that is committed to providing healthcare professionals with the information and resources they need to make informed treatment decisions. Senores Pharmaceuticals has established a strong distribution network to ensure that its products are readily available to patients around the world. In addition to its own product portfolio, Senores Pharmaceuticals is actively seeking partnerships and licensing agreements to expand its offerings and address a wider range of medical needs. The company is dedicated to building long-term relationships with healthcare providers, payers, and patient advocacy groups to improve access to care and promote positive health outcomes.

Company Details

Symbol:SENORES
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Swapnil Jatinbhai Shah
MD & Director
Mr. Deval Rajnikant Shah
Whole-Time Director & CFO
Mr. Chetan Bipinchandra Shah
Whole-Time Director & COO

SENORES Share Price: Frequently Asked Questions

What is the current share price of Senores Pharmaceuticals Limited?

Senores Pharmaceuticals Limited (SENORES) trades at ₹1376.90 on NSE and BSE. Market cap ₹6.34K (Cr). Educational data only.

What is the P/E ratio of Senores Pharmaceuticals Limited?

Senores Pharmaceuticals Limited has a P/E of 48.48x vs industry average 34.89x.

What is the Bull Run score for Senores Pharmaceuticals Limited?

Senores Pharmaceuticals Limited has a Bull Run score of 44.7/100 based on 25+ financial parameters.

Does Senores Pharmaceuticals Limited pay dividends?

Senores Pharmaceuticals Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Senores Pharmaceuticals Limited?

Senores Pharmaceuticals Limited has ROE of 0.00%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Senores Pharmaceuticals Limited?

Senores Pharmaceuticals Limited has debt-to-equity of 0.35.

Is Senores Pharmaceuticals Limited a good investment?

Bull Run gives Senores Pharmaceuticals Limited a score of 44.7/100. This is not investment advice — consult a SEBI-registered advisor.